Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand 
Alphabet Earnings Surge on AI Growth, Cloud Revenue, and Strong Search Performance 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
GAITHERSBURG, Md., May 01, 2017 -- Novavax, Inc. (Nasdaq:NVAX) today announced it will report its first quarter 2017 financial and operating results following the close of U.S. financial markets on Monday, May 8, 2017.
Conference call details are as follows:
| Date: | Monday, May 8, 2017 | ||
| Time: | 4:30 p.m. U.S. Eastern Time (ET) | ||
| Dial-in number: | (877) 212-6076 (Domestic) or (707) 287-9331 (International) | ||
| Passcode: | 15607801 | ||
| Webcast: | www.novavax.com, “Investors”/ “Events” | ||
Conference call and webcast replay:
| Dates: | Starting at 7:30 p.m. ET, May 8, 2017, until 7:30 p.m. ET, May 15, 2017 | ||
| Dial-in number: | (855) 859-2056 (Domestic) or (404) 537-3406 (International) | ||
| Passcode: | 15607801 | ||
| Webcast: | www.novavax.com, “Investors”/ “Events” | ||
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biotechnology company committed to delivering novel products to prevent a broad range of infectious diseases. Its recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines.
Contact: Investor Relations Novavax, Inc. Andrea N. Flynn, Ph.D. Associate Director, Investor Relations [email protected] 240-268-2000 Westwicke Partners John Woolford [email protected] 443-213-0506 Media Russo Partners, LLC David Schull Todd Davenport, Ph.D. [email protected] 212-845-4271
